Examining the Effect of Burosumab on Muscle Function
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness
particularly after exertion, in addition to their skeletal complaints. In previous trials
using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The
investigators wish to test this hypothesis directly by measuring muscle energy when patients
begin treatment with Crysvita® for the first time.